证券代码：603882 证券简称：金域医学 公告编号：2026-003 广州金域医学检验集团股份有限公司 关于预计与金圻睿2026年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次日常关联交易事项无需经公司股东会审议。 日常关联交易对上市公司的影响：公司及下属企业与关联人金圻睿的日 常关联交易为因日常经营活动所需而发生的正常业务往来，遵循公平、公正、公 开的原则，不会对公司的生产经营和财务状况产生重大影响，公司的主营业务也 不会因此而形成依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 广州金域医学检验集团股份有限公司（以下简称"公司"）于2026年1月5 日召开第四届董事会第九次会议，审议通过了《关于预计与广州市金圻睿生物科 技有限责任公司2026年度日常关联交易的议案》，由于本项议案涉及关联交易， 关联董事梁耀铭先生、严婷女士、曾湛文先生以及解强先生回避表决，其余五位 非关联董事一致同意并通过了该议案。 该关联交易事项已经公司独立董事专门会议审议通过，独立董事一致 ...

广州金域医学检验集团股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 (一)股东会类型和届次 2026年第一次临时股东会 证券代码：603882 证券简称：金域医学 公告编号：2026-006 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2026 年 1 月 21 日 14 点 30 分 召开地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 21 日 至2026 年 1 月 21 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 ...

证券代码：603882 证券简称：金域医学 公告编号：2026-001 广州金域医学检验集团股份有限公司 第四届董事会第九次会议决议公告 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第 九次会议于 2026 年 1 月 5 日以通讯方式召开，会议通知已于 2025 年 12 月 26 日以电子形式发出。会议由董事长梁耀铭先生主持，本次会议应出席董事 9 名， 实际出席董事 9 名。公司高级管理人员列席本次会议。会议召开符合《中华人民 共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票 表决方式通过以下决议： （一）审议通过《广州金域医学检验集团股份有限公司 2025 年前三季度利 润分配预案》 经审议，董事会同意公司实施 2025 年前三季度分红：以实施权益分派股权 登记日登记的总股本为基数，每股派发现金红利 0.88 元（含税）。具体内容详见 同日于上海证券交易所网站（www.sse.com.cn）及公司指定披露媒体《中国证券 报》、《上海证券报》、《证券日报》、《证券时报》刊登的《广州金域医学检验集团 股 ...

广州金域医学检验集团股份有限公司 关于 2025 年前三季度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：A 股每股派发现金红利 0.88 元（含税） 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 证券代码：603882 证券简称：金域医学 公告编号：2026-002 如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股、回 购股份、股权激励授予股份回购注销或重大资产重组股份回购注销等致使公司总 股本发生变动的，公司拟维持每股分配比例不变，相应调整分配总额。如后续总 股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交公司 2026 年第一次临时股东会审议。 二、公司履行的决策程序 公司于 2026 年 1 月 5 日召开第四届董事会第九次会议，以 9 票同意，0 票 反对，0 票弃权 ...

Core Viewpoint - The company, Kingmed Diagnostics (金域医学), announced a cash dividend distribution plan to enhance investor returns and promote shared benefits from the company's operational growth, while ensuring sustainable and long-term development [1] Dividend Distribution Plan - The company plans to distribute a cash dividend of 8.80 yuan (including tax) for every 10 shares held, based on the total share capital registered on the dividend distribution date [1] - As of the announcement date, the total share capital of the company is 463,258,275 shares, leading to a total proposed cash dividend payout of 407,667,282.00 yuan (including tax) [1]

格隆汇1月5日丨金域医学(603882.SH)公布，为增强投资者回报，促进全体股东共享公司经营发展成 果，提升投资者获得感，切实保护广大投资者利益，在保证公司持续稳健经营及长远发展的前提下，结 合公司所处发展阶段、实际经营情况、未来发展规划等因素，公司拟实施2025年前三季度分红。本次利 润分配方案如下：以实施权益分派股权登记日登记的总股本为基数，向全体股东每10股派发现金红利 8.80元（含税），剩余未分配利润结转以后年度分配。截至本公告披露日，公司总股本为463,258,275 股，以此计算本次合计拟派发现金红利407,667,282.00元（含税）。 ...

金域医学公告称，2026年1月5日公司第四届董事会第九次会议审议通过预计与金圻睿2026年度日常关联 交易的议案。2025年公司预计与金圻睿交易2.40亿元，1 - 11月累计已发生交易2.21亿元。2026年预计交 易2.22亿元，其中向其采购商品预计2.20亿元，占同类业务不超15%；向其提供劳务预计150万元，占同 类业务不超5%。金圻睿为佳鉴公司全资子公司，因股东关联关系被认定为关联人，其财务指标正常， 履约能力良好。 ...

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The pharmaceutical sector is experiencing a phase of oscillation and differentiation, with a recommendation to seize thematic rotation and bottom adjustment opportunities, particularly in the innovative drug supply chain and AI+ sectors [6][13] - The long-term growth driver for the pharmaceutical sector is technological innovation, with key focuses on "continuation of policy benefits," "breakthroughs in frontier technologies," and "international BD transactions" [6][13] - The report highlights the potential of new generation CTLA-4 therapies that address toxicity issues, thereby unlocking market potential [7] Summary by Sections Industry Overview - The pharmaceutical industry comprises 499 listed companies with a total market value of 71,291.29 billion [2] - The industry is currently valued at 25.8 times PE based on 2025 earnings forecasts, with a premium of 10.2% over the overall A-share market [22] Market Dynamics - The report notes a 14.49% return for the pharmaceutical sector since the beginning of 2025, underperforming the CSI 300 index by 1.60 percentage points [19] - Recent market movements show a decline in the pharmaceutical sector, with specific segments like pharmaceutical commerce and medical devices showing positive growth [19][6] Key Recommendations - Focus on companies involved in innovative drug development and AI applications, such as 恒瑞医药 (Hengrui Medicine), 中国生物制药 (China National Pharmaceutical Group), and 康方生物 (Kangfang Biopharma) [6][13] - The report emphasizes the importance of addressing clinical pain points and enhancing safety in new generation immuno-oncology drugs [7] Notable Companies - The report recommends several companies for investment, including 康方生物 (Kangfang Biopharma), 药明合联 (WuXi AppTec), and 泰格医药 (Tigermed) [7][30] - It highlights the performance of specific stocks, noting that the average decline for 中泰医药 (Zhongtai Medicine) was 2.51% this month, while it outperformed the industry by 0.68% this week [29][30]